Table of Contents
Introduction
The Global Coronary Stents Market size is expected to be worth around USD 24.0 Billion by 2032 from USD 13.4 Billion in 2023, growing at a CAGR of 6.9% during the forecast period from 2024 to 2032.
The coronary stents market is experiencing growth driven by several key factors. One significant driver is the increasing prevalence of coronary artery disease (CAD), which affects millions of people and is a leading cause of death worldwide. This rise in heart disease has intensified the demand for effective treatment options, including the use of stents during percutaneous coronary interventions (PCI) to enhance blood flow to the heart.
Technological advancements are also playing a crucial role in market expansion. The development of drug-eluting stents, which release medication to prevent artery re-narrowing, has been a major breakthrough. Innovations like fully absorbable stents, such as the Absorb GT1 Bioresorbable Vascular Scaffold System, represent ongoing progress in stent technology. These advancements aim to improve patient outcomes by reducing complications such as restenosis and blood clots.
Additionally, the aging population is contributing to the increased demand for coronary interventions. Older adults are more susceptible to cardiovascular diseases, and while lifestyle changes and medication are effective, stenting offers significant quality-of-life improvements for patients experiencing symptoms like chest pain. This underscores the essential role of coronary stents in modern cardiology and highlights their importance in the expanding market.
Key Takeaways
- Market Size: The Global Coronary Stents Market size is expected to be worth around USD 24.0 Billion by 2032 from USD 13.4 Billion in 2023.
- Market Growth: The Global Coronary Stents Market is growing at a CAGR of 6.9% during the forecast period from 2024 to 2032.
- Product Analysis: A bioabsorbable segment is expected to witness the highest growth during the forecast period.
- Development Analysis: The estimated dominance of self-expanding stents in the market is primarily due to clinically proven and emerging local and regional manufacturers worldwide.
- End-User Analysis: Hospital Segment Dominating the Global Coronary Stents Market Size
- Regional Analysis: With a share of 39.4%, North America dominated the coronary stent market and contributed the most revenue.
- Increasing Demand: The rising prevalence of cardiovascular diseases, an aging population, and a growing preference for minimally invasive procedures are driving the demand for coronary stents.
- Innovative Developments: Recent developments include Medtronic’s launch of the Onyx Frontier stent in Europe and its subsequent FDA approval in the U.S. These stents are designed to enhance deliverability and performance.
- Challenges: The market faces several challenges, including cost constraints in developing regions, post-procedural complications, and stringent regulatory requirements.
Coronary Stents Statistics
- Coronary Artery Disease Prevalence: Coronary artery disease affects about 18 million Americans and is the leading cause of death in the United States.
- Stent Usage: Approximately 1 million coronary stents are implanted in the United States each year.
- Types of Stents: There are primarily two types of stents used in coronary procedures: bare-metal stents and drug-eluting stents.
- Effectiveness: Drug-eluting stents are known to reduce the risk of restenosis (re-narrowing of the artery) by about 50% compared to bare-metal stents.
- Restenosis Rate: Bare-metal stents have a restenosis rate of approximately 20-30%, while drug-eluting stents reduce this rate to less than 10%.
- Stent Thrombosis: Stent thrombosis, a potentially serious complication, occurs in about 0.5-2.0% of patients who receive stents.
- Survival Rate: Studies indicate no significant difference in survival rates between patients treated with stents and those treated with medication and lifestyle changes for stable ischemic heart disease.
- Quality of Life: Stenting and bypass surgery provide better symptom relief and quality of life for patients with chest pain compared to medication alone.
- Recovery: Most patients can resume normal activities within a week after a coronary stenting procedure.
- Follow-up Care: After receiving a stent, patients typically require dual antiplatelet therapy (DAPT) for at least 6-12 months to prevent blood clots.
- Antiplatelet Therapy: Long-term use of antiplatelet medication after stent placement reduces the risk of heart attack and death by 20-30%.
- Coronary Artery Disease Risk Factors: Major risk factors for coronary artery disease include high blood pressure, high cholesterol, smoking, and diabetes.
- Gender Disparity: Men are generally at higher risk for coronary artery disease than women until women reach menopause, after which their risk increases.
- Global Impact: Cardiovascular diseases, including those requiring stents, account for approximately 17.9 million deaths annually worldwide.
Company Analysis
- Abbott: In July 2024, Abbott introduced the latest generation of their XIENCE drug-eluting stents, featuring advanced delivery system enhancements. This launch aims to improve patient outcomes by enabling easier stent delivery in complex anatomies.
- Medtronic: In June 2024, Medtronic expanded its stent offerings with the launch of the Resolute Onyx drug-eluting stent in Asia. This stent features a unique CoreWire technology for better flexibility and conformability.
- Boston Scientific Corporation: In August 2024, Boston Scientific announced the European launch of the Synergy XD Bioabsorbable Polymer Drug-Eluting Stent System, designed to enhance drug elution and vessel healing.
- Terumo Corporation: In May 2024, Terumo announced the acquisition of a novel stent technology from a European medical device firm. This acquisition aims to broaden Terumo’s product portfolio in interventional cardiology.
- B. Braun Melsungen AG: In July 2024, B. Braun launched its latest generation of coronary stents, featuring a new coating technology to reduce restenosis and improve patient outcomes.
- Biotronik: In March 2024, Biotronik introduced the Orsiro Mission Drug-Eluting Stent in the United States, which is designed for superior deliverability and long-term safety in coronary interventions.
- Stentys SA: In April 2024, Stentys announced a merger with a leading European cardiovascular device company to expand their market reach and enhance their coronary stent product line.
Emerging Trends:
- Technological Advancements: Drug-eluting stents (DES) are a cornerstone of the coronary stents market, featuring advanced polymer coatings that improve drug release, reduce clot formation, and minimize restenosis. Innovations like biocompatible materials and enhanced delivery systems improve patient safety and efficacy, making DES a preferred choice.
- Bioabsorbable Stents: Bioabsorbable stents dissolve after use, maintaining natural vessel flexibility and reducing risks associated with permanent implants. They leave behind a healed artery, potentially decreasing complications like late stent thrombosis, aligning with goals to reduce long-term intervention issues.
- Minimally Invasive Procedures: Percutaneous coronary interventions (PCI) are favored over open-heart surgeries due to smaller incisions, quicker recovery, less pain, and lower infection risk. This shift towards minimally invasive procedures improves patient outcomes and reflects a broader trend in healthcare.
- Focus on Personalized Medicine: Personalized medicine tailors stent designs to individual patient needs, enhancing success and minimizing adverse effects. Customization involves adjusting stent size, drug formulation, and release rates, leading to improved outcomes and emphasizing personalized care in cardiology.
- Integration with Digital Health: Stents integrated with digital health technologies, such as smart sensors, provide real-time data on stent performance and vascular health. This enables remote monitoring and proactive management of cardiovascular conditions, supporting a more connected healthcare system.
- Regulatory Approvals: Regulatory approvals from bodies like the FDA ensure new stent designs meet safety and efficacy standards, facilitating their clinical use. These approvals drive innovation, offering improved delivery mechanisms and enhanced safety profiles, benefiting patients with advanced technologies.
- Focus on Cost-effectiveness: Efforts to make stents cost-effective expand access, especially in developing regions. Strategies include bulk purchasing, local manufacturing, and efficient production to lower prices, improving patient outcomes and addressing health disparities by making stents more affordable.
- Increased Use of Imaging Techniques: Advanced imaging techniques like intravascular ultrasound (IVUS) and optical coherence tomography (OCT) improve coronary stenting precision. They guide stent placement, ensuring optimal positioning and minimizing complications, leading to better long-term outcomes and enhanced patient safety.
Use Cases
- Angina Relief: Coronary stents restore blood flow in blocked arteries, relieving angina symptoms. This improves patients’ daily life and enhances long-term heart health by maintaining open arteries.
- Heart Attack Treatment: During heart attacks, stents are used to quickly open blocked arteries, reducing heart damage and complications. This intervention improves survival rates and recovery outcomes.
- Post-Bypass Surgery: Stents help maintain blood flow in patients with new blockages after coronary artery bypass grafting (CABG), extending the benefits of the initial surgery and preventing symptom recurrence.
- Coronary Artery Disease Management: For coronary artery disease (CAD), stents keep arteries open post-angioplasty, reducing heart attack risk and improving long-term prognosis when medication alone is insufficient.
- Minimally Invasive Alternative: Stenting is less invasive than coronary artery bypass grafting (CABG), leading to shorter hospital stays, faster recovery, and reduced complications, making it a patient-friendly option.
- Recurrent Blockage Prevention: Drug-eluting stents release medication to prevent artery restenosis, reducing the need for repeat procedures and enhancing long-term arterial health and patient outcomes.
- Improving Quality of Life: Stents improve the quality of life for ischemic heart disease patients by reducing chest pain and enhancing heart function, allowing more active lifestyles.
- High-Risk Patients: For high-risk patients unsuitable for open-heart surgery, stents offer a safer, less invasive treatment with fewer complications and risks.
- Immediate Intervention: In acute coronary syndrome (ACS), stents quickly restore blood flow, preventing further heart damage and aiding faster recovery.
Conclusion:
The coronary stents market is poised for significant growth, driven by technological advancements and a rising demand for minimally invasive procedures. The market is expected to grow substantially over the coming years, with drug-eluting stents leading the market due to their effectiveness in reducing restenosis rates. Innovations in stent design, such as bioresorbable and polymer-free stents, offer promising alternatives that enhance patient outcomes and reduce complications. The aging global population and increasing prevalence of cardiovascular diseases are also contributing to the expansion of the market. Regional growth is strong in North America, due to technological advancements and healthcare infrastructure, and in the Asia Pacific, with increasing healthcare investments and regulatory reforms driving market expansion.
Discuss Your Needs With Our Analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
